

Publisher: Bentham Science Publishers
E-ISSN: 1873-5592|16|11|1187-1197
ISSN: 1389-4501
Source: Current Drug Targets, Vol.16, Iss.11, 2015-10, pp. : 1187-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




Amfebutamone for second-line treatment only
Inpharma, Vol. 1, Iss. 1309, 2001-01 ,pp. :




Bevacizumab: In First-Line Treatment of Metastatic Breast Cancer
Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. :


Venlafaxine worthwhile for first-line depression treatment in the UK
Inpharma, Vol. 1, Iss. 1436, 2004-01 ,pp. :